Carlsmed (NASDAQ:CARL) COO Sells 747 Shares of Company Stock

Carlsmed, Inc. (NASDAQ:CARL) COO Jeffrey Bertolini sold 747 shares of the company’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $14.39, for a total value of $10,749.33. Following the completion of the transaction, the chief operating officer directly owned 22,489 shares in the company, valued at $323,616.71. This trade represents a 3.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Jeffrey Bertolini also recently made the following trade(s):

• On Wednesday, September 30th, Jeffrey Bertolini sold 243 shares of Carlsmed stock. The stock was sold at an average price of $13.99, for a total value of $3,399.57.

Carlsmed Trading Down 4.3%

Shares of CARL traded down $0.66 during trading hours on Tuesday, reaching $14.64. 116,185 shares of the company traded hands, compared to its average volume of 138,367. The stock’s fifty day moving average price is $14.79 and its 200 day moving average price is $12.14. The company has a current ratio of 8.84, a quick ratio of 8.66 and a debt-to-equity ratio of 0.18. The firm has a market cap of $399.67 million, a price-to-earnings ratio of -10.24 and a beta of 2.09. Carlsmed, Inc. has a 12-month low of $8.50 and a 12-month high of $17.23.

Carlsmed (NASDAQ:CARL) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.01. Carlsmed had a negative net margin of 57.42% and a negative return on equity of 38.06%. The company had revenue of $18.94 million for the quarter. Sell-side analysts forecast that Carlsmed, Inc. will post -1.5 earnings per share for the current year.

Analyst Ratings Changes

CARL has been the topic of a number of research reports. Needham & Company LLC began coverage on shares of Carlsmed in a research report on Wednesday, July 1st. They set a “buy” rating and a $17.00 target price on the stock. Weiss Ratings raised Carlsmed from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Truist Financial raised their price objective on Carlsmed from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wall Street Zen raised Carlsmed from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, BTIG Research reissued a “buy” rating and set a $23.00 price target on shares of Carlsmed in a research report on Monday, September 28th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Carlsmed currently has an average rating of “Moderate Buy” and an average target price of $19.25.

Institutional Investors Weigh In On Carlsmed

Several large investors have recently modified their holdings of CARL. Deutsche Bank AG purchased a new stake in shares of Carlsmed in the 2nd quarter worth approximately $106,000. Bank of America Corp DE purchased a new position in Carlsmed during the second quarter valued at approximately $108,000. Alpine Woods Capital Investors LLC bought a new position in Carlsmed in the second quarter worth approximately $161,000. Bank of New York Mellon Corp bought a new position in Carlsmed in the second quarter worth approximately $181,000. Finally, KCM Capital Inc purchased a new stake in Carlsmed during the first quarter worth $1,810,000.

Carlsmed Company Profile

Carlsmed, Inc is a medical technology company focused on personalized solutions for spine surgery. The company develops patient-specific implants and digital planning tools intended to help surgeons address spinal deformity and degenerative conditions with procedures tailored to an individual patient’s anatomy and surgical goals.

Its principal products are offered under the aprevo brand and include personalized interbody fusion implants produced using three-dimensional printing, along with software that supports implant design and preoperative planning.